WO 2005/080551

1	Clai	<u>ms</u>
2		
3	1.	A human embryonic stem cell line
4		characterised by at least one of the
5		following:
6		i) presence of the cell surface markers TR
7		1-60, GTCM2, and SSEA-4;
8		ii) expression of Oct-4;
9		iii) expression of NANOG;
0		iv) expression of REX-1; and/or
1		expression of TERT.
2		
3	2.	The human stem cell line as claimed in Claim
4		1 having two or more of the characteristics
5		i) to v).
6		
7	3.	The human stem cell line as claimed in Claim
8		2 having three or more of the characteristic
9		i) to v).
0		
1	4.	The human stem cell line as claimed in Claim
2		3 having four of the characteristics i) to
3		v).
4		
5	5.	The human stem cell line as claimed in Claim
6	•	4 having all of the characteristics i) to v)
7		
8	6.	The stem cell line hES-NCL1 deposited at
9		NIBSC under Accession No. P-05-001.
0		
1	7.	An embryonic stem cell bank comprising a
2		multiplicity of genetically distinct stem

38

PCT/GB2005/000518

1	cell	lines as claimed in any one of Claims 1
2	to 6	
3		
4	8. A me	thod of screening an agent for toxicity
5	and/	or for therapeutic efficacy, said method
6	comp	rising:
7	i.	exposing a stem cell line as claimed in
8		any one of Claims 1 to 6 to said agent;
9	ii.	monitoring any alteration in viability
10		and/or metabolism of said stem cells; and
11	iii.	determining any toxic or therapeutic
12		effect of said agent.
13		
14	9. A me	thod of screening an agent for toxicity
15	and/	or for therapeutic efficacy, said method
16	comp	rising:
17	i.	exposing an embryonic stem cell bank as
18		claimed in Claim 7 to said agent;
19	ii.	monitoring any alteration in viability
20		and/or metabolism of said stem cells; .
21		and
22	iii.	determining any toxic or therapeutic
23		effect of said agent.
24		
25	10. A me	thod of producing fibroblast-like cells,
26	said	method comprising:
27	i.	providing a stem cell line as claimed in
28		any one of Claims 1 to 6;
29	ii.	allowing cells of said stem cell line to
30		differentiate into stem cell derived
31		fibroblast-like cells.

40

The method of Claim 10 which is conducted 11. 1 without use of a specific stimulant for 2 differentiation. 3 4 5 12. The method as claimed in either one of Claims 10 and 11 wherein the fibroblast-like cells б are produced for a therapeutic purpose. 7 8 A method of culturing cells wherein the 13. 9 fibroblast-like cells obtained as claimed in 10 Claims 10 or 11 act as feeder cells or 11 condition cell culture media used during 12 culture of the cells. 13 14 The method as claimed in Claim 13 wherein the 15 14. cells being cultured are stem cells. 16 17 A method of maintaining the viability of eggs 15. 18 19 prior to or during fertilisation, wherein the 20 fibroblast-like cells obtained as claimed in Claims 10 or 11 act as feeder cells or 21 condition cell culture media used during 22 maintenance of the eggs. . 23 24 25 16. A method of culturing a blastocyst or embryo prior to implantation into a receptive 26 female, wherein the fibroblast-like cells 27 obtained as claimed in Claims 10 or 11 act as 28 feeder cells or condition cell culture media 29 used during culture of the blastocyst or 30 31 embryo. 32

41
17. The fibroblast-like cell line hESCdF-NCL as

PCT/GB2005/000518

deposited at ECACC under Accession No.

3 04010601.

WO 2005/080551

4

1

5 18. A method of culturing cells wherein hESCdF-

6 NCL cells act as feeder cells or condition

7 cell culture media used during culture of the

8 cells.

9

10 19. The method as claimed in Claim 18 wherein the

cells being cultured are stem cells.

12

13 20. A method of maintaining the viability of eggs

prior to or during fertilisation, wherein

15 hescdf-NCL cells act as feeder cells or

16 condition cell culture media used during

maintenance of the eggs.

18

19 21. A method of culturing a blastocyst or embryo

20 prior to implantation into a receptive

female, wherein hESCdF-NCL cells act as

feeder cells or condition cell culture media

used during culture of the blastocyst or

embryo.

25

26 22. A self-feeder system for the growth of

27 undifferentiated stem cells, said system

comprising:

i. culturing a stem cell line as claimed in

any one of Claims 1 to 6; and

ii. and allowing some of the cells of said

32 stem cell line to differentiate into

1		stem cell derived fibroblast-like cells
2		whilst the remainder of the cells of
3		said embryonic stem cell line remain in
4		an undifferentiated pluripotent,
5		multipotent or unipotent state, whereby
6		said stem cell derived fibroblast-like
7		cells act as autogeneic feeder cells for
8		said stem cells.
9		
10	23.	A method of culturing a blastocyst, said
11		method comprising exposing said blastocyst
12		for a period of at least 12 hours to Buffalo
13		rat liver cells or to media conditioned by
14		Buffalo rat liver cells.
15		
16	24.	The method as claimed in Claim 23 wherein the
17		period of exposure is at least 48 hours.
18		
19	25.	The method as claimed in either one of Claims
20		23 and 24 wherein the period of exposure of
21		said blastocyst to said Buffalo rat liver
22		cells or to media conditioned by said Buffalo
23	,	rat liver cells immediately precedes
24		extraction of ICM cells from the blastocyst.
25		
26	26.	The method as claimed in any one of Claims 23
27		to 25 wherein the media conditioned by
28	•	Buffalo rat liver cells is produced by:
29		i. culturing at least 75000 Buffalo rat
30		liver cells/cm ² in Glasgow medium for 24
31		to 36 hours; and

43

recovering the media by removal of the ii. 1 cells. 2 3 The method as claimed in any one of Claims 23 27. 4 to 26 wherein the blastocyst can be cultured 5 to day 8 after fertilisation and retain 6 pluripotency. 7 8 The method as claimed in any one of Claims 23 28. 9 to 27 wherein said blastocyst is a primate 10 blastocyst. 11 12 13 The method as claimed in Claim 28 wherein 29. 14 said blastocyst is a human blastocyst. 15 A method for culturing a blastocyst, as 16 30. 17 claimed in any one of Claims 23 to 29, said method comprising: 18 19 culturing said blastocyst from i. 20 fertilisation in G1 media; transferring said blastocyst of step ii. 21 i) to G2.3 media and maintaining said 22 23 blastocyst in the G2.3 media; and transferring said blastocyst of step 24 iii. ii) to cell culture media conditioned 25 26 by Buffalo rat liver cells. 27 The method as claimed in Claim 30 wherein the 28 31. 29 blastocyst is cultured in the conditions of step i. for 1 to 3 days. 30 31

44 The method as claimed in either one of Claims 32. 1 30 and 31 wherein the blastocyst is cultured 2 in the conditions of step ii. for 2 to 3 3 4 days. 5 The method as claimed in any one of Claims 30 6 33. to 32 wherein the blastocyst is cultured in 7 8 the conditions of step iii. for 1 to 3 days. 9 The method as claimed in any one of Claims 30 10 34. to 33 wherein the cell culture media is 11 12 Dulbecco's modified Eagle's medium optionally supplemented with 15% (v/v) Glasgow medium 13 14 and conditioned by Buffalo rat liver cells. 15 35. A method of in vitro fertilisation, said 16 method comprising culturing a blastocyst as 17 18 claimed in any one of Claims 23 to 34; and 19 implanting said cultured blastocyst into a 20 receptive female. 21 22 A method of producing an embryonic stem cell 36. 23 line, said method comprising: 24 culturing a blastocyst as claimed in any 25 one of Claims 23 to 34; and extracting cells of the inner cell mass 26 ii. 27 (ICM) from said blastocyst and culturing 28 the cells to produce an embryonic stem cell line therefrom. 29

45

The method as claimed in Claim 36 wherein 37. 1 2 said stem cell line is a primate embryonic stem cell line. 3 4 The method as claimed in Claim 37 wherein 5 38. said stem cell line is a non-human primate 6 embryonic stem cell line. 8 The method as claimed in Claim 37 wherein 39. 9 said stem cell line is a human embryonic stem 10 cell line. 11 12 The method as claimed in any one of Claims 36 13 40. 14 to 38 wherein said embryonic stem cell line is a pluripotent stem cell line. 15 16 A self-feeder system for the growth of 17 41. 18 undifferentiated stem cells, said system 19 comprising: 20 i. culturing a blastocyst as claimed in Claims 23 to 34; 21 extracting cells of the ICM from said 22 ii. blastocyst and culturing the cells to 23 24 produce an embryonic stem cell line therefrom; and 25 and allowing some of the cells of said 26 iii. embryonic stem cell line to differentiate 27 into stem cell derived fibroblast-like 28 cells whilst the remainder of the cells 29 of said embryonic stem cell line remain 30 in an undifferentiated pluripotent, 31 32 multipotent or unipotent state, whereby

1		said stem cell derived fibroblast-like
2		cells act as autogeneic feeder cells for
3		said stem cells.
4		
5	42.	An embryonic stem cell bank comprising a
6		multiplicity of genetically distinct stem
7		cell lines obtained by the method as claimed
8		in any one of Claims 36 to 39.
9		
10	43.	A method of producing fibroblast-like cells,
11		said method comprising:
12		i. culturing a blastocyst as claimed in any
13		one of Claims 23 to 34;
14		ii. extracting cells of the ICM from said
15		blastocyst and culturing the cells to
16		produce an embryonic stem cell line
17		therefrom; and
18	i	ii. allowing cells of said embryonic stem
19		cell line to differentiate into stem cel
20		derived fibroblast-like cells.
21		
22	44.	A method of culturing cells wherein the
23		fibroblast-like cells obtained by the method
24		of Claim 43 act as feeder cells or condition
25		cell culture media used during culture of the
26		cells.
27		
28	45.	A method of maintaining the viability of eggs
29		prior to or during fertilisation wherein the
30		fibroblast-like cells obtained by the method
31		of Claim 43 act as feeder cells or condition

47

cell culture media used during maintenance of the eggs.

3

4 46. A method of a blastocyst or embryo prior to
5 implantation into a receptive female wherein
6 the fibroblast-like cells obtained by the
7 method of Claim 43 act as feeder cells or
8 condition cell culture media used during
9 culture of blastocyst or embryo.